Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retigabine and riluzole effects on peripheral motor nerve excitability in ALS
2015-001431-20Phase 2Completed
- Sponsor
- Centre for Human Drug Research
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Sequence including retigabine (Trobalt), Sequence including riluzole (Rilutek) and Sequence including placebo (3 arms). Primary endpoint: ICC for nerve excitability parameters. Started Apr 2015; status: completed.
02
Drugs
retigabineriluzole
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2015-001431-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001431-20.